[Pathophysiological and clinical evaluation of the effectiveness of dalargin in the treatment of arterial occlusive diseases of the lower extremities].
Eighty seven patients with Stages II-III vascular occlusions in the lower extremities were examined. The clinical and biochemical parameters of the course of the disease were found to improve in the patients who received in earlier periods dalargin supplemented to the combined therapy than in those from a matched group. There was a decrease in femoral venous blood lactate concentrations in the diseased extremity, blood cholesterol and parathyroid hormone levels. The mechanisms responsible for effects of dalargin on metabolic parameters and clinical indices of the patients' condition were also discussed. Whether it is possible to use dalargin in the combined therapy for extremity vascular occlusive diseases is considered.
Zoloev
G K
GK
Dudko
V A
VA
Sokolovich
G E
GE
Poiarkov
V D
VD
Ponurovskiĭ
Beloglazov
M E
ME
Ivatsin
N P
NP
Stepanian
N A
NA
Shil'nikov
M G
MG
D000328:Adult; D000924:Anticholesteremic Agents; D001162:Arteriosclerosis Obliterans / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood*; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007773:Lactates / Q000037:antagonists & inhibitors / Q000097:blood*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000037:antagonists & inhibitors / Q000097:blood*
D000924:Anticholesteremic Agents; D007773:Lactates; D010281:Parathyroid Hormone; D016308:Enkephalin, Leucine-2-Alanine; D002784:Cholesterol; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
Patofiziologicheskaia i klinicheskaia otsenka éffektivnosti dalargina pri lechenii obliteriruiushchikh zabolevaniĭ arteriĭ nizhnikh konechnosteĭ.